<?xml version = '1.0' encoding = 'UTF-8'?>
<?xml-stylesheet href="/rss/styledrssBMC.css" type="text/css"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:extra="http://www.biomedcentral.com/xml/schemas/extra/" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" xmlns:cc="http://web.resource.org/cc/">
	<channel rdf:about="http://www.biomedcentral.com/rss">
		<extra:info rdf:parseType="Literal">
			<html:div xmlns:html="http://www.w3.org/1999/xhtml" style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif">
				<html:span style="font-weight:bold">This is an RSS newsfeed from BioMed Central</html:span>
				<html:br/>
				<html:span style="font-size: 12px;">It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit <html:br/><html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">http://www.biomedcentral.com/info/about/rss/</html:a><html:br/>
				</html:span>
			</html:div>
		</extra:info>
		<title>BMC Pediatrics - Most viewed articles</title>
		<link>http://www.biomedcentral.com/bmcpediatr/mostviewed/</link>
		<description>Most viewed articles in last 30 days from BMC Pediatrics (ISSN 1471-2431) published by 
				
				BioMed Central
		</description>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
         <items>
            <rdf:Seq>
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2431/8/13"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2431/3/13"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2431/8/14"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2431/8/27"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2431/7/24"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2431/8/24"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2431/8/26"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2431/8/21"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2431/8/25"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2431/7/36"/>			    
            
            </rdf:Seq>
        </items>
    </channel>
    
		<item rdf:about="http://www.biomedcentral.com/1471-2431/8/13">
            
            <title>Kangaroo mother care diminishes pain from heel lance in very preterm neonates: A crossover trial</title>
			<description>Background:
Skin-to-skin contact, or kangaroo mother care (KMC) has been shown to be efficacious in diminishing pain response to heel lance in full term and moderately preterm neonates. The purpose of this study was to determine if KMC would also be efficacious in very preterm neonates.
Methods:
Preterm neonates (n = 61) between 28 0/7 and 31 6/7 weeks gestational age in three Level III NICU's in Canada comprised the sample. A single-blind randomized crossover design was employed. In the experimental condition, the infant was held in KMC for 15 minutes prior to and throughout heel lance procedure. In the control condition, the infant was in prone position swaddled in a blanket in the incubator. The primary outcome was the Premature Infant Pain Profile (PIPP), which is comprised of three facial actions, maximum heart rate, minimum oxygen saturation levels from baseline in 30-second blocks from heel lance. The secondary outcome was time to recover, defined as heart rate return to baseline. Continuous video, heart rate and oxygen saturation monitoring were recorded with event markers during the procedure and were subsequently analyzed. Repeated measures analysis-of-variance was employed to generate results.
Results:
PIPP scores at 90 seconds post lance were significantly lower in the KMC condition (8.871 (95%CI 7.852&#8211;9.889) versus 10.677 (95%CI 9.563&#8211;11.792) p &lt; .001) and non-significant mean differences ranging from 1.2 to1.8. favoring KMC condition at 30, 60 and 120 seconds. Time to recovery was significantly shorter, by a minute(123 seconds (95%CI 103&#8211;142) versus 193 seconds (95%CI 158&#8211;227). Facial actions were highly significantly lower across all points in time reaching a two-fold difference by 120 seconds post-lance and heart rate was significantly lower across the first 90 seconds in the KMC condition.
Conclusion:
Very preterm neonates appear to have endogenous mechanisms elicited through skin-to-skin maternal contact that decrease pain response, but not as powerfully as in older preterm neonates. The shorter recovery time in KMC is clinically important in helping maintain homeostasis.Trial Registration(Current Controlled Trials) ISRCTN63551708</description>
			<link>http://www.biomedcentral.com/1471-2431/8/13</link>		
			<dc:creator>C Celeste Johnston, Francoise Filion, Marsha Campbell-Yeo, Celine Goulet, Linda Bell, Kathryn McNaughton, Jasmine Byron, Marilyn Aita, G Allen Finley and Claire-Dominique Walker</dc:creator>
			<dc:source>BMC Pediatrics 2008, 8:13</dc:source>
			<dc:subject>Number of accesses: 3783</dc:subject>
			<dc:date>2008-04-24</dc:date>
			<dc:identifier>doi:10.1186/1471-2431-8-13</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pediatrics</prism:publicationName>
					
			
							
					<prism:issn>1471-2431</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>13</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-04-24</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2431/3/13">
            
            <title>A new growth chart for preterm babies: Babson and Benda's chart updated with recent data and a new format</title>
			<description>Background:
The Babson and Benda 1976 "fetal-infant growth graph" for preterm infants is commonly used in neonatal intensive care. Its limits include the small sample size which provides low confidence in the extremes of the data, the 26 weeks start and the 500 gram graph increments. The purpose of this study was to develop an updated growth chart beginning at 22 weeks based on a meta-analysis of published reference studies.
Methods:
The literature was searched from 1980 to 2002 for more recent data to complete the pre and post term sections of the chart. Data were selected from population studies with large sample sizes. Comparisons were made between the new chart and the Babson and Benda graph. To validate the growth chart the growth results from the National Institute of Child Health and Human Development Neonatal Research Network (NICHD) were superimposed on the new chart.
Results:
The new data produced curves that generally followed patterns similar to the old growth graph. Mean differences between the curves of the two charts reached statistical significance after term. Babson's 10th percentiles fell between the new data percentiles: the 5th to 17th for weight, the 5th and 15th for head circumference, and the 6th and 16th for length. The growth patterns of the NICHD infants deviated away from the curves of the chart in the first weeks after birth. When the infants reached an average weight of 2 kilograms, those with a birthweight in the range of 700 to 1000 grams had achieved greater than the 10th percentile on average for head growth, but remained below the 3rd percentile for weight and length.
Conclusion:
The updated growth chart allows a comparison of an infant's growth first with the fetus as early as 22 weeks and then with the term infant to 10 weeks. Comparison of the size of the NICHD infants at a weight of 2 kilograms provides evidence that on average preterm infants are growth retarded with respect to weight and length while their head size has caught up to birth percentiles. As with all meta-analyses, the validity of this growth chart is limited by the heterogeneity of the data sources. Further validation is needed to illustrate the growth patterns of preterm infants to older ages.</description>
			<link>http://www.biomedcentral.com/1471-2431/3/13</link>		
			<dc:creator>Tanis R Fenton</dc:creator>
			<dc:source>BMC Pediatrics 2003, 3:13</dc:source>
			<dc:subject>Number of accesses: 2184</dc:subject>
			<dc:date>2003-12-16</dc:date>
			<dc:identifier>doi:10.1186/1471-2431-3-13</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pediatrics</prism:publicationName>
					
			
							
					<prism:issn>1471-2431</prism:issn>
					
			
							
					<prism:volume>3</prism:volume>
					
			
							
					<prism:startingPage>13</prism:startingPage>
					
			
							
					<prism:publicationDate>2003-12-16</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2431/8/14">
            
            <title>Effectiveness of physical therapy interventions for children with cerebral palsy: A systematic review</title>
			<description>Background:
To assess the effectiveness of physical therapy (PT) interventions on functioning in children with cerebral palsy (CP).
Methods:
A search was made in Medline, Cinahl, PEDro and the Cochrane library for the period 1990 to February 2007. Only randomized controlled trials (RCTs) on PT interventions in children with diagnosed CP were included. Two reviewers independently assessed the methodological quality and extracted the data. The outcomes measured in the trials were classified using the International Classification of Functioning, Disability and Health (ICF).
Results:
Twenty-two trials were identified. Eight intervention categories were distinguished. Four trials were of high methodological quality. Moderate evidence of effectiveness was established for two intervention categories: effectiveness of upper extremity treatments on attained goals and active supination, and of prehensile hand treatment and neurodevelopmental therapy (NDT) or NDT twice a week on developmental status, and of constraint-induced therapy on amount and quality of hand use. Moderate evidence of ineffectiveness was found of strength training on walking speed and stride length. Conflicting evidence was found for strength training on gross motor function. For the other intervention categories the evidence was limited due to low methodological quality and the statistically insignificant results of the studies.
Conclusion:
Due to limitations in methodological quality and variations in population, interventions and outcomes, mostly limited evidence on the effectiveness of most PT interventions is available through RCTs. Moderate evidence was found for some effectiveness of upper extremity training. Well-designed trials are needed especially for focused PT interventions.</description>
			<link>http://www.biomedcentral.com/1471-2431/8/14</link>		
			<dc:creator>Heidi Anttila, Ilona Autti-R&#228;m&#246;, Jutta Suoranta, Marjukka M&#228;kel&#228; and Antti Malmivaara</dc:creator>
			<dc:source>BMC Pediatrics 2008, 8:14</dc:source>
			<dc:subject>Number of accesses: 565</dc:subject>
			<dc:date>2008-04-24</dc:date>
			<dc:identifier>doi:10.1186/1471-2431-8-14</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pediatrics</prism:publicationName>
					
			
							
					<prism:issn>1471-2431</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>14</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-04-24</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2431/8/27">
            
            <title>Idiopathic central precocious puberty in girls: presentation factors</title>
			<description>Background:
It is sometimes difficult to distinguish between premature thelarche and precocious puberty in girls who develop breasts before the age of 8 years. We evaluated the frequencies of the signs associated with breast development and the factors influencing the presentation of girls with idiopathic central precocious puberty (CPP).
Methods:
353 girls monitored 0.9 &#177; 0.7 year after the onset of CPP.
Results:
The age at CPP was &lt; 3 years in 2%, 3&#8211;7 years in 38% and 7&#8211;8 years in 60% of cases. Pubic hair was present in 67%, growth rate greater than 2 SDS in 46% and bone age advance greater than 2 years in 33% of cases. Breast development was clinically isolated in 70 (20%) cases. However, only 31 of these (8.8% of the population) had a prepubertal length uterus and gonadotropin responses to gonadotropin releasing hormone and plasma estradiol. The clinical picture of CPP became complete during the year following the initial evaluation.25% of cases were obese. The increase in weight during the previous year (3.7 &#177; 1.4 kg) and body mass index were positively correlated with the statural growth and bone age advance (P &lt; 0.0001).There was no relationship between the clinical-biological presentation and the age at puberty, the interval between the onset of puberty and evaluation, or the presence of familial CPP.
Conclusion:
The variation in presentation of girls with CPP does not depend on their age, interval between the onset and evaluation, or familial factors. This suggests that there are degrees of hypothalamic-pituitary-ovarian activation that are not explained by these factors.</description>
			<link>http://www.biomedcentral.com/1471-2431/8/27</link>		
			<dc:creator>G&#233;raldine Pr&#233;t&#233;, Ana-Claudia Couto-Silva, Christine Trivin and Raja Brauner</dc:creator>
			<dc:source>BMC Pediatrics 2008, 8:27</dc:source>
			<dc:subject>Number of accesses: 536</dc:subject>
			<dc:date>2008-07-04</dc:date>
			<dc:identifier>doi:10.1186/1471-2431-8-27</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pediatrics</prism:publicationName>
					
			
							
					<prism:issn>1471-2431</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>27</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-07-04</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2431/7/24">
            
            <title>Leukocyte counts in urine reflect the risk of concomitant sepsis in bacteriuric infants: A retrospective cohort study</title>
			<description>Background:
When urine infections are missed in febrile young infants with normal urinalysis, clinicians may worry about the risk &#8211; hitherto unverified &#8211; of concomitant invasion of blood and cerebrospinal fluid by uropathogens. In this study, we determine the extent of this risk.
Methods:
In a retrospective cohort study of febrile 0&#8211;89 day old infants evaluated for sepsis in an urban academic pediatric emergency department (1993&#8211;1999), we estimated rates of bacteriuric sepsis (urinary tract infections complicated by sepsis) after stratifying infants by urine leukocyte counts higher, or lower than 10 cells/hpf. We compared the global accuracy of leukocytes in urine, leukocytes in peripheral blood, body temperature, and age for predicting bacteruric sepsis. The global accuracy of each test was estimated by calculating the area under its receiver operating characteristic curve (AUC). Chi-square and Fisher exact tests compared count data. Medians for data not normally distributed were compared by the Kruskal-Wallis test.
Results:
Two thousand two hundred forty-nine young infants had a normal screening dipstick. None of these developed bacteremia or meningitis despite positive urine culture in 41 (1.8%). Of 1516 additional urine specimens sent for formal urinalysis, 1279 had 0&#8211;9 leukocytes/hpf. Urine pathogens were isolated less commonly (6% vs. 76%) and at lower concentrations in infants with few, compared to many urine leukocytes. Urine leukocytes (AUC: 0.94) were the most accurate predictors of bacteruric sepsis. Infants with urinary leukocytes &lt; 10 cells/hpf were significantly less likely (0%; CI:0&#8211;0.3%) than those with higher leukocyte counts (5%; CI:2.6&#8211;8.7%) to have urinary tract infections complicated by bacteremia (N = 11) or bacterial meningitis (N = 1) &#8211; relative risk, 0 (CI:0&#8211;0.06) [RR, 0 (CI: 0&#8211;0.02), when including infants with negative dipstick]. Bands in peripheral blood had modest value for detecting bacteriuric sepsis (AUC: 0.78). Cases of sepsis without concomitant bacteriuria were comparatively rare (0.8%) and equally common in febrile young infants with low and high concentrations of urine leukocytes.
Conclusion:
In young infants evaluated for fever, leukocytes in urine reflect the likelihood of bacteriuric sepsis. Infants with urinary tract infections missed because of few leukocytes in urine are at relatively low risk of invasive bacterial sepsis by pathogens isolated from urine.</description>
			<link>http://www.biomedcentral.com/1471-2431/7/24</link>		
			<dc:creator>Bema K Bonsu and Marvin B Harper</dc:creator>
			<dc:source>BMC Pediatrics 2007, 7:24</dc:source>
			<dc:subject>Number of accesses: 531</dc:subject>
			<dc:date>2007-06-13</dc:date>
			<dc:identifier>doi:10.1186/1471-2431-7-24</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pediatrics</prism:publicationName>
					
			
							
					<prism:issn>1471-2431</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>24</prism:startingPage>
					
			
							
					<prism:publicationDate>2007-06-13</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2431/8/24">
            
            <title>Placental determinants of fetal growth: identification of key factors in the insulin-like growth factor and cytokine systems using artificial neural networks</title>
			<description>Background:
Changes and relationships of components of the cytokine and IGF systems have been shown in placenta and cord serum of fetal growth restricted (FGR) compared with normal newborns (AGA). This study aimed to analyse a data set of clinical and biochemical data in FGR and AGA newborns to assess if a mathematical model existed and was capable of identifying these two different conditions in order to identify the variables which had a mathematically consistent biological relevance to fetal growth.
Methods:
Whole villous tissue was collected at birth from FGR (N = 20) and AGA neonates (N = 28). Total RNA was extracted, reverse transcribed and then real-time quantitative (TaqMan) RT-PCR was performed to quantify cDNA for IGF-I, IGF-II, IGFBP-1, IGFBP-2 and IL-6. The corresponding proteins with TNF-&#945; in addition were assayed in placental lysates using specific kits. The data were analysed using Artificial Neural Networks (supervised networks), and principal component analysis and connectivity map.
Results:
The IGF system and IL-6 allowed to predict FGR in approximately 92% of the cases and AGA in 85% of the cases with a low number of errors. IGF-II, IGFBP-2, and IL-6 content in the placental lysates were the most important factors connected with FGR. The condition of being FGR was connected mainly with the IGF-II placental content, and the latter with IL-6 and IGFBP-2 concentrations in placental lysates.
Conclusion:
These results suggest that further research in humans should focus on these biochemical data. Furthermore, this study offered a critical revision of previous studies. The understanding of this system biology is relevant to the development of future therapeutical interventions possibly aiming at reducing IL-6 and IGFBP-2 concentrations preserving IGF bioactivity in both placenta and fetus.</description>
			<link>http://www.biomedcentral.com/1471-2431/8/24</link>		
			<dc:creator>Maria E Street, Enzo Grossi, Cecilia Volta, Elena Faleschini and Sergio Bernasconi</dc:creator>
			<dc:source>BMC Pediatrics 2008, 8:24</dc:source>
			<dc:subject>Number of accesses: 465</dc:subject>
			<dc:date>2008-06-17</dc:date>
			<dc:identifier>doi:10.1186/1471-2431-8-24</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pediatrics</prism:publicationName>
					
			
							
					<prism:issn>1471-2431</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>24</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-06-17</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2431/8/26">
            
            <title>TIPIT: A randomised controlled trial of thyroxine in preterm infants under 28 weeks gestation: Magnetic Resonance Imaging and Magnetic Resonance Angiography protocol</title>
			<description>Abstract 
Background:
Infants born at extreme prematurity are at high risk of developmental disability. A major risk factor for disability is having a low level of thyroid hormone described as hypothyroxinaemia, which is recognised to be a frequent phenomenon in these infants. Derangements of critical thyroid function during the sensitive window in prematurity when early development occurs, may have a range of long term effects for brain development. Further research in preterm infants using neuroimaging techniques will increase our understanding of the specificity of the effects of hypothyroxinaemia on the developing foetal brain. This is an explanatory double blinded randomised controlled trial which is aimed to assess the effect of thyroid hormone supplementation on brain size, key brain structures, extent of myelination, white matter integrity and vessel morphology, somatic growth and the hypothalamic-pituitary-adrenal axis.
Methods:
The study is a multi-centred double blinded randomised controlled trial of thyroid hormone supplementation in babies born below 28 weeks' gestation. All infants will receive either levothyroxine or placebo until 32 weeks corrected gestational age. The primary outcomes will be width of the sub-arachnoid space measured using cranial ultrasound and head circumference at 36 weeks corrected gestational age. The secondary outcomes will be thyroid hormone concentrations, the hypothalamic pituitary axis status and auxological data between birth and expected date of delivery; thyroid gland volume, brain size, volumes of key brain structures, extent of myelination and brain vessel morphology at expected date of delivery and markers of morbidity which include duration of mechanical ventilation and/or oxygen requirement and chronic lung disease.Trial registrationCurrent Controlled Trials ISRCTN89493983</description>
			<link>http://www.biomedcentral.com/1471-2431/8/26</link>		
			<dc:creator>Sze M Ng, Mark A Turner, Carrol Gamble, Mohammed Didi, Suresh Victor, Christina Malamateniou, Laura M Parkes, Anna Tietze, Lloyd Gregory, Vanessa Sluming, Laurence Abernethy and Alan M Weindling</dc:creator>
			<dc:source>BMC Pediatrics 2008, 8:26</dc:source>
			<dc:subject>Number of accesses: 440</dc:subject>
			<dc:date>2008-06-30</dc:date>
			<dc:identifier>doi:10.1186/1471-2431-8-26</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pediatrics</prism:publicationName>
					
			
							
					<prism:issn>1471-2431</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>26</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-06-30</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2431/8/21">
            
            <title>The diagnostic work up of growth failure in secondary health care; An evaluation of consensus guidelines</title>
			<description>Background:
As abnormal growth might be the first manifestation of undetected diseases, it is important to have accurate referral criteria and a proper diagnostic work-up. In the present paper we evaluate the diagnostic work-up in secondary health care according to existing consensus guidelines and study the frequency of underlying medical disorders.
Methods:
Data on growth and additional diagnostic procedures were collected from medical records of new patients referred for short stature to the outpatient clinics of the general paediatric departments of two hospitals (Erasmus MC &#8211; Sophia Children's Hospital, Rotterdam and Spaarne Hospital, Haarlem) between January 1998 and December 2002. As the Dutch Consensus Guideline (DCG) is the only guideline addressing referral criteria as well as diagnostic work-up, the analyses were based on its seven auxological referral criteria to determine the characteristics of children who are incorrectly referred and the adequacy of workup of those who are referred.
Results:
Twenty four percent of children older than 3 years were inappropriately referred (NCR). Of the correctly referred children 74&#8211;88% were short corrected for parental height, 40&#8211;61% had a height SDS &lt;-2.5 and 21% showed height deflection (&#916; HSDS &lt; -0.25/yr or &#916; HSDS &lt; -1). In none of the children a complete detailed routine diagnostic work up was performed and in more than 30% no routine laboratory examination was done at all. Pathologic causes of short stature were found in 27 children (5%).
Conclusion:
Existing guidelines for workup of children with suspected growth failure are poorly implemented. Although poorly implemented the DCG detects at least 5% pathologic causes of growth failure in children referred for short stature. New guidelines for referral are required with a better sensitivity and specificity, wherein distance to target height should get more attention. The general diagnostic work up for short stature should include testing for celiac disease in all children and for Turner syndrome in girls.</description>
			<link>http://www.biomedcentral.com/1471-2431/8/21</link>		
			<dc:creator>Floor K Grote, Wilma Oostdijk, Sabine MPF De Muinck Keizer-Schrama, Paula van Dommelen, Stef van Buuren, Friedo W Dekker, Arnoldus G Ketel, Henriette A Moll and Jan M Wit</dc:creator>
			<dc:source>BMC Pediatrics 2008, 8:21</dc:source>
			<dc:subject>Number of accesses: 414</dc:subject>
			<dc:date>2008-05-13</dc:date>
			<dc:identifier>doi:10.1186/1471-2431-8-21</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pediatrics</prism:publicationName>
					
			
							
					<prism:issn>1471-2431</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>21</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-05-13</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2431/8/25">
            
            <title>The usefulness of growth hormone treatment for psychological status in young adult survivors of childhood leukaemia: an open-label study</title>
			<description>Background:
To reduce the risk of brain damage children with acute lymphoblastic leukaemia (ALL) are nowadays mainly treated with intrathecal chemotherapy (ITC) instead of central nervous system (CNS) radiation therapy (CRT) to prevent CNS relapse. However, chemotherapy may also lead to cognitive deficits. As growth hormone deficiency (GHD) or impaired growth hormone secretion are frequently found in ALL patients treated with cranial radiation therapy and/or chemotherapy, we hypothesized that GH therapy may reduce cognitive deficits in these patients.
Methods:
Twenty young adult survivors of childhood ALL with reduced bone mineral density (&lt;-1 SD) and/or low IGF-I SD-scores (&lt;-1 SD) were included in the study. A final group of 13 patients (9 males and 4 females), mean age 23.7 &#177; 2.9 years (range 20 &#8211; 29.7) completed a 2-year treatment with GH.IQ and neuropsychological performance were assessed at pre-treatment (T1) and after one (T2) and two (T3) years. ANOVA was performed with assessment at T1, T2 and T3 as repeated measurements factor. Relations between test score changes and changes of IGF-I levels were determined by calculating the Pearson correlation coefficient.
Results:
Scores on the cognitive tests were in the normal range. Verbal short- and long-term memory performance decreased between T1 and T2, and increased between T2 and T3. Performance at T3 was not significantly different from that at T1. Performance for sustained attention improved from T1 to T2 and from T1 to T3. Visual-spatial memory was improved after one year of GH treatment. A significant positive correlation was found for &#916; IGF-I (T2-T1) with difference scores of visual-spatial memory (T2-T1 and T3-T1), indicating that IGF-I increase after one year of GH treatment is associated with increase in cognitive-perceptual performance at month 12 and 24.
Conclusion:
Since the level of intellectual functioning of our patient cohort was in the normal range the present finding that GH treatment has negative effects on verbal memory and positive on attention and visual-spatial memory warrants similar studies in other groups of ALL survivors. Also, a lower dose of GH should be determined inducing as much IGF as needed to improve verbal as well as visual cognitive functions. The present findings indicate that more knowledge is needed before GH treatment may be recommended to enhance cognitive functions in ALL survivors.</description>
			<link>http://www.biomedcentral.com/1471-2431/8/25</link>		
			<dc:creator>Jaap Huisman, Eline J Aukema, Jan Berend Deijen, Silvia CCM van Coeverden, Gertjan JL Kaspers, Heleen JH van der Pal and Henriette A Delemarre-van de Waal</dc:creator>
			<dc:source>BMC Pediatrics 2008, 8:25</dc:source>
			<dc:subject>Number of accesses: 375</dc:subject>
			<dc:date>2008-06-20</dc:date>
			<dc:identifier>doi:10.1186/1471-2431-8-25</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pediatrics</prism:publicationName>
					
			
							
					<prism:issn>1471-2431</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>25</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-06-20</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2431/7/36">
            
            <title>The effects of hyperbaric oxygen therapy on oxidative stress, inflammation, and symptoms in children with autism: an open-label pilot study</title>
			<description>Background:
Recently, hyperbaric oxygen therapy (HBOT) has increased in popularity as a treatment for autism. Numerous studies document oxidative stress and inflammation in individuals with autism; both of these conditions have demonstrated improvement with HBOT, along with enhancement of neurological function and cognitive performance. In this study, children with autism were treated with HBOT at atmospheric pressures and oxygen concentrations in current use for this condition. Changes in markers of oxidative stress and inflammation were measured. The children were evaluated to determine clinical effects and safety.
Methods:
Eighteen children with autism, ages 3&#8211;16 years, underwent 40 hyperbaric sessions of 45 minutes duration each at either 1.5 atmospheres (atm) and 100% oxygen, or at 1.3 atm and 24% oxygen. Measurements of C-reactive protein (CRP) and markers of oxidative stress, including plasma oxidized glutathione (GSSG), were assessed by fasting blood draws collected before and after the 40 treatments. Changes in clinical symptoms, as rated by parents, were also assessed. The children were closely monitored for potential adverse effects.
Results:
At the endpoint of 40 hyperbaric sessions, neither group demonstrated statistically significant changes in mean plasma GSSG levels, indicating intracellular oxidative stress appears unaffected by either regimen. A trend towards improvement in mean CRP was present in both groups; the largest improvements were observed in children with initially higher elevations in CRP. When all 18 children were pooled, a significant improvement in CRP was found (p = 0.021). Pre- and post-parental observations indicated statistically significant improvements in both groups, including motivation, speech, and cognitive awareness (p &lt; 0.05). No major adverse events were observed.
Conclusion:
In this prospective pilot study of children with autism, HBOT at a maximum pressure of 1.5 atm with up to 100% oxygen was safe and well tolerated. HBOT did not appreciably worsen oxidative stress and significantly decreased inflammation as measured by CRP levels. Parental observations support anecdotal accounts of improvement in several domains of autism. However, since this was an open-label study, definitive statements regarding the efficacy of HBOT for the treatment of individuals with autism must await results from double-blind, controlled trials.Trial Registrationclinicaltrials.gov NCT00324909</description>
			<link>http://www.biomedcentral.com/1471-2431/7/36</link>		
			<dc:creator>Daniel A Rossignol, Lanier W Rossignol, S Jill James, Stepan Melnyk and Elizabeth Mumper</dc:creator>
			<dc:source>BMC Pediatrics 2007, 7:36</dc:source>
			<dc:subject>Number of accesses: 364</dc:subject>
			<dc:date>2007-11-16</dc:date>
			<dc:identifier>doi:10.1186/1471-2431-7-36</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pediatrics</prism:publicationName>
					
			
							
					<prism:issn>1471-2431</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>36</prism:startingPage>
					
			
							
					<prism:publicationDate>2007-11-16</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
		
	<cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
         <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks"/>
	</cc:License>
</rdf:RDF>
